$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000139047818000010 Filed on May 15, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.909M	$3.880M	$2.287M
YoY Change	27.81%	69.65%	-35.12%
% of Gross Profit
Research & Development	$1.592M	$1.804M	$2.184M
YoY Change	-12.86%	-17.4%	-59.88%
% of Gross Profit
Depreciation & Amortization	$0.00		$26.00K
YoY Change	-100.0%		333.33%
% of Gross Profit
Operating Expenses	$6.501M	$5.684M	$4.471M
YoY Change	14.7%	27.13%	-50.14%
Operating Profit			-$5.088M
YoY Change			-43.26%
Interest Expense	-$120.0K	-$100.0K	-$130.0K
YoY Change	-7.69%	-23.08%	-96.72%
% of Operating Profit
Other Income/Expense, Net	-$5.899M	-$2.220M	$0.00
YoY Change	1.78%		-100.0%
Pretax Income	-$5.900M	-$8.000M	-$4.600M
YoY Change	1.72%	73.91%	-64.89%
Income Tax	$163.0K
% Of Pretax Income
Net Earnings	-$6.062M	-$7.995M	-$4.601M
YoY Change	2.52%	73.77%	-72.1%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.45
Diluted Earnings Per Share	-$43.29M	-$66.67M	-$153.3M
COMMON SHARES
Basic Shares Outstanding	6.655M shares		26.41M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.300M	$3.500M	$27.60M
YoY Change	-92.82%	-87.32%	-20.46%
Cash & Equivalents	$1.300M	$3.474M	$18.10M
Short-Term Investments
Other Short-Term Assets	$9.500M	$9.600M	$14.40M
YoY Change	-33.1%	-33.33%	336.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$10.93M	$13.07M	$42.05M
YoY Change	-66.17%	-68.91%	10.8%
LONG-TERM ASSETS
Property, Plant & Equipment			$173.0K
YoY Change			-42.14%
Goodwill	$1.914M	$1.914M	$5.898M
YoY Change	-67.55%	-67.55%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.500M	$900.0K	$100.0K
YoY Change	1400.0%	800.0%	0.0%
Total Long-Term Assets	$21.05M	$20.41M	$28.29M
YoY Change	-25.53%	-27.83%	-0.46%
TOTAL ASSETS
Total Short-Term Assets	$10.93M	$13.07M	$42.05M
Total Long-Term Assets	$21.05M	$20.41M	$28.29M
Total Assets	$31.97M	$33.49M	$70.33M
YoY Change	-47.2%	-52.39%	5.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.10M	$11.45M	$1.163M
YoY Change	3042.6%	884.61%	14.13%
Accrued Expenses	$4.974M	$4.470M	$3.189M
YoY Change	88.84%	40.17%	-21.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.779M	$8.526M	$12.60M
YoY Change	-40.28%	-32.32%	236.82%
Total Short-Term Liabilities	$24.85M	$25.75M	$36.27M
YoY Change	-28.05%	-29.01%	-14.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$1.150M	$0.00
YoY Change
Other Long-Term Liabilities	$7.900M	$6.200M	$1.200M
YoY Change	558.33%	416.67%	-80.95%
Total Long-Term Liabilities	$0.00	$1.150M	$1.200M
YoY Change	-100.0%	-4.17%	-80.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.85M	$25.75M	$36.27M
Total Long-Term Liabilities	$0.00	$1.150M	$1.200M
Total Liabilities	$34.46M	$34.80M	$43.14M
YoY Change	-16.83%	-19.32%	-20.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.24M	-$62.18M
YoY Change	-78.88%
Common Stock	$65.76M	$60.86M	$345.7M
YoY Change	-81.0%	-82.39%	10.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$3.849M
YoY Change			0.0%
Treasury Stock Shares			675.0K shares
Shareholders Equity	-$2.483M	-$1.318M	$27.19M
YoY Change
Total Liabilities & Shareholders Equity	$31.97M	$33.49M	$70.33M
YoY Change	-47.2%	-52.39%	5.98%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$6.062M	-$7.995M	-$4.601M
YoY Change	2.52%	73.77%	-72.1%
Depreciation, Depletion And Amortization	$0.00		$26.00K
YoY Change	-100.0%		333.33%
Cash From Operating Activities	-$6.300M	-$5.403M	-$3.803M
YoY Change	106.56%	42.07%	-71.22%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$18.00K
YoY Change			-98.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$15.52M
YoY Change			-23.11%
Debt Paid & Issued, Net		$589.0K	$0.00
YoY Change			-100.0%
Cash From Financing Activities	4.210M	$4.739M	$0.00
YoY Change	-25.62%		-100.0%
NET CHANGE
Cash From Operating Activities	-6.300M	-$5.403M	-$3.803M
Cash From Investing Activities			-$18.00K
Cash From Financing Activities	4.210M	$4.739M	$0.00
Net Change In Cash	-2.090M	-$664.0K	-$3.803M
YoY Change	-180.08%	-82.54%	-176.38%
FREE CASH FLOW
Cash From Operating Activities	-$6.300M	-$5.403M	-$3.803M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q4	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P5Y
CY2018Q1	gale	Closing Price Of Common Stock ClosingPriceOfCommonStock	3.45
CY2018Q1	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	115000	shares
CY2018Q1	gale	Common Stock Issued During The Period For Cancellation Of Warrants CommonStockIssuedDuringThePeriodForCancellationOfWarrants	54613	shares
CY2018Q1	gale	Common Stock Shares Acquiredin Exchangefor Warrants CommonStockSharesAcquiredinExchangeforWarrants	379333	shares
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6655155	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	SELLAS Life Sciences Group, Inc.
CY2018Q1	dei	Trading Symbol TradingSymbol	SLS
CY2017Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	0	USD
CY2018Q1	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	1881000	USD
CY2017Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	0	USD
CY2018Q1	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-3411000	USD
CY2017Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	0	USD
CY2018Q1	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-3411000	USD
CY2018Q1	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-1881000	USD
CY2018Q1	gale	Class Of Warrant Or Right Canceled ClassOfWarrantOrRightCanceled	501000	shares
CY2018Q1	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	774000	shares
CY2018Q1	gale	Classof Warrantor Right Surrenderedand Canceledto Purchase Common Stock ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock	121667	shares
CY2018Q1	gale	Consideration Exchanged Fair Value ConsiderationExchangedFairValue	1200000	USD
CY2017Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1294000	USD
CY2018Q1	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	4705000	USD
CY2017Q4	gale	Contract Research Payable ContractResearchPayable	51000	USD
CY2018Q1	gale	Contract Research Payable ContractResearchPayable	960000	USD
CY2017Q1	gale	Conversionwith Series A Convertible Preferred Stock ConversionwithSeriesAConvertiblePreferredStock	0	USD
CY2018Q1	gale	Conversionwith Series A Convertible Preferred Stock ConversionwithSeriesAConvertiblePreferredStock	1968000	USD
CY2018Q1	gale	Debt Instrument Redemption Principal Amount Redeemed Settled In Cash DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash	600000	USD
CY2018Q1	gale	Dividend On Conversion Of Series A Convertible Preferred Stock DividendOnConversionOfSeriesAConvertiblePreferredStock	1968000	USD
CY2018Q1	gale	Convertible Preferred Stock Dividends ConvertiblePreferredStockDividends	-72000	USD
CY2018Q1	gale	Debt Instrument Redemption Principal Amount Redeemed DebtInstrumentRedemptionPrincipalAmountRedeemed	1600000	USD
CY2018Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	1500000	USD
CY2018Q1	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y11M12D
CY2018Q1	gale	Fair Value Of Warrants Canceled FairValueOfWarrantsCanceled	487000	USD
CY2017Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	1309000	USD
CY2018Q1	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	1528000	USD
CY2017Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	1309000	USD
CY2018Q1	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	1528000	USD
CY2018Q1	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	2587000	USD
CY2017Q4	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	5.60
CY2017Q4	gale	In Process Research Development InProcessResearchDevelopment	17600000	USD
CY2018Q1	gale	In Process Research Development InProcessResearchDevelopment	17600000	USD
CY2017Q1	gale	Longterm Debt Issued In Connection With Warrant Exchanges LongtermDebtIssuedInConnectionWithWarrantExchanges	0	USD
CY2018Q1	gale	Longterm Debt Issued In Connection With Warrant Exchanges LongtermDebtIssuedInConnectionWithWarrantExchanges	888000	USD
CY2017Q1	gale	Loss On Settlement Of Liability Classified Warrants LossOnSettlementOfLiabilityClassifiedWarrants	0	USD
CY2018Q1	gale	Loss On Settlement Of Liability Classified Warrants LossOnSettlementOfLiabilityClassifiedWarrants	-685000	USD
CY2017Q1	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	0	USD
CY2018Q1	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	685000	USD
CY2018Q1	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	700000	USD
CY2018Q1	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	401000	shares
CY2017Q4	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	223000	USD
CY2018Q1	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	416000	USD
CY2017Q1	gale	Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock	0	USD
CY2018Q1	gale	Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock	285000	USD
CY2018Q1	gale	Restricted Stock Shares Reservedfor Future Issuance RestrictedStockSharesReservedforFutureIssuance	13000	shares
CY2018Q1	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	0	USD
CY2018Q1	gale	Warrant Exchange Agreements Amount WarrantExchangeAgreementsAmount	285000	USD
CY2018Q1	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	17200000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11691000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11451000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3201000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4470000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1744000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1898000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	56254000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	60861000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-1968000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	22000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2587000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	937000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22000	USD
CY2017Q4	us-gaap	Assets Assets	33526000	USD
CY2018Q1	us-gaap	Assets Assets	33485000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	13087000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	13072000	USD
CY2017Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.87
CY2017Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.87
CY2017Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-6753000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2319000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3474000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5962000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2159000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12750000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12086000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3803000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-664000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.42
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	316163	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	963000	shares
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1236000	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3225000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5766891	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6154377	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5766891	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6154377	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5766891	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2018Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1631000	USD
CY2018Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	314228	shares
CY2018Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	1045000	shares
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	4471000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	5684000	USD
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5800000	USD
CY2017Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	10200000	USD
CY2018Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	8000000	USD
CY2017Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	10988000	USD
CY2018Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	9676000	USD
CY2018Q1	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	1900000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1673000	USD
CY2018Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1673000	USD
CY2017Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	925000	USD
CY2018Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	899000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.63
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.67
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	505000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	566000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1881000	USD
CY2017Q4	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2017Q4	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
CY2017Q4	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.9010
CY2017Q4	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0220
CY2018Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0
CY2017Q4	us-gaap	Goodwill Goodwill	1914000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	1914000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4601000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7995000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3585000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-240000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3838000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1197000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-114000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	622000	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-130000	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-96000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	110000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	31456000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	34803000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33526000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33485000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24569000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	25747000	USD
CY2017Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1300000	USD
CY2018Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1300000	USD
CY2018Q1	us-gaap	Long Term Debt LongTermDebt	9700000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8377000	USD
CY2018Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	8526000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2611000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1150000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4739000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3803000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5403000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-4601000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-7995000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4601000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9963000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	265000	USD
CY2017Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-130000	USD
CY2018Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2311000	USD
CY2017Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2018Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	20000	USD
CY2017Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2018Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1968000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5987	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5987	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	337000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	986000	USD
CY2017Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	0	USD
CY2018Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	34000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	5328000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	589000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2184000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1804000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10431000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8612000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54185000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62180000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2287000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3880000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	937000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	22000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8005
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0271
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1240.55
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	405000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.70
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	415000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1240.55
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.03
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.22
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M16D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P9M
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y8M12D
CY2018Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1631000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5328000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2070000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-1318000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2070000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1318000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	426000	USD
CY2018Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	426000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1268489	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5952193	shares

Files In Submission

Name	View Source	Status
0001390478-18-000010-index-headers.html	Edgar Link	pending
0001390478-18-000010-index.html	Edgar Link	pending
0001390478-18-000010.txt	Edgar Link	pending
0001390478-18-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20180331.xml	Edgar Link	completed
gale-20180331.xsd	Edgar Link	pending
gale-20180331_cal.xml	Edgar Link	unprocessable
gale-20180331_def.xml	Edgar Link	unprocessable
gale-20180331_lab.xml	Edgar Link	unprocessable
gale-20180331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sellas-logoa03.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
sls-20180331x10q.htm	Edgar Link	pending
sls20180331ex1024.htm	Edgar Link	pending
sls20180331ex311.htm	Edgar Link	pending
sls20180331ex312.htm	Edgar Link	pending
sls20180331ex321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2018 Q2 Form 10-Q Financial Statement

#000139047818000010 Filed on May 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2018 Q2 Form 10-Q Financial Statement

#000139047818000010 Filed on May 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls